Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab plus intratumoral interleukin-2 in pretreated stage IV melanoma
2010-019033-98Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and aldesleukin in melanoma, sponsored by University Hospital Tübingen. Primary endpoints: Immune related Disease control rate and Tolerability. Started Aug 2011; status: completed.
02
Drugs
ipilimumabaldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on 2010-019033-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019033-98.